January 22, 2024

IN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data

IN8bio (NASDAQ:INAB) is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these cells to effectively target and eliminate cancer cells in both solid and hematological tumors. IN8bio’s pipeline consists of a range of preclinical and clinical investigational therapies that aim to address various types of cancer with large unmet needs.